HAIR Restoration Robotics Inc

Restoration Robotics® Receives European CE Mark Approval for the ARTAS iX™ Robotic Hair Restoration System

Restoration Robotics® Receives European CE Mark Approval for the ARTAS iX™ Robotic Hair Restoration System

SAN JOSE, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Restoration Robotics, Inc. (NASDAQ: HAIR), announced today that it received CE Mark approval for the sale of the ARTAS iX™ System with implantation functionality in Europe. The CE Mark approval follows the Company’s receipt of ISO 13485:2016 Certification for ARTAS iX in January 2019.

Ryan Rhodes, President and Chief Executive Officer of Restoration Robotics, states, “We are very pleased to announce our receipt of CE mark approval, which further expands our addressable market for ARTAS iX. With this approval ARTAS users in Europe will have the ability to leverage our new platform which includes novel implantation functionality, optimizes clinical outcomes, and further improves hair restoration process workflow. In these geographies, we will continue to sell through our international sales team and our distributor partners, as we maintain our focus on expanding our commercial presence globally.”

The ARTAS® Robotic Hair Restoration System is the first and only hair restoration system in the world combining robotic and artificial intelligence technology designed to assist surgeons through the most significant and tedious stages of the hair restoration process. It allows for precise, efficient, and repeatable hair restoration and automates the most significant aspects of hair transplantation procedures: graft harvesting, recipient site making, and now, implantation. ARTAS iX™ features an advanced stereoscopic machine vision system with improved 44-micron resolution and a 7-axis robot arm to deliver unmatched procedural analysis, precision, repeatability, and clinical workflow efficiency.

For more information on the ARTAS® iX system, please visit 

About Restoration Robotics

Restoration Robotics, Inc. is a medical device company developing and commercializing the ARTAS® and ARTAS iX™ Robotic Hair Restoration Systems. The ARTAS iX System is the first and only physician-assisted system to dissect and assist in the harvesting of follicular units directly from the scalp, create recipient implant sites using proprietary algorithms and implant the hair follicles into the designated sites. The Company has unique expertise in machine vision, image guidance, visual servoing and robotics, as well as developing intuitive interfaces to manage these technologies. ARTAS iX is currently approved in Europe and the United States.

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this document are based on current beliefs, assumptions and expectations, speak only as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements, including our expectations and plans for expanding our presence in Europe and globally generally, are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: the progress of our commercialization, marketing and manufacturing capabilities; and the timing or likelihood of regulatory filings and approvals for ARTAS for use in transplanting of hair. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on August 14, 2019, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Media Contact

Lisa Markle 

Director of Marketing 

Restoration Robotics, Inc. 



Investor Contact

The Ruth Group

Carol Ruth/Kaitlyn Brosco

+1 (646) 536-7000

EN
15/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Restoration Robotics Inc

 PRESS RELEASE

Venus Concept Announces Fourth Quarter and Fiscal Year 2019 Financial ...

Venus Concept Announces Fourth Quarter and Fiscal Year 2019 Financial Results; Provides Preliminary First Quarter of 2020 Revenue Results and Updates Fiscal Year 2020 Revenue Guidance TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months and twelve months ended December 31, 2019 and preliminary revenue results for the three months ending March 31, 2020. The Company notes that the financial results provided for the three months and twelv...

 PRESS RELEASE

Venus Concept Inc. Announces $22.25 Million Equity Financing

Venus Concept Inc. Announces $22.25 Million Equity Financing TORONTO, March 18, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Compa...

 PRESS RELEASE

Venus Concept to Release Fourth Quarter and Fiscal Year 2019 Financial...

Venus Concept to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 30, 2020 TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Monday, March 30. Management will host a conference call at 5:00 p.m. Eastern Time on March 30 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may di...

 PRESS RELEASE

Venus Concept Expands Executive Team

Venus Concept Expands Executive Team Chad A. Zaring, Appointed Chief Commercial Officer TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that it has expanded its Executive Team with the appointment of Chad A. Zaring to the newly-created role of Chief Commercial Officer (“CCO”), effective February 10, 2020. Mr. Zaring has extensive experience in building and executing commercial strategies and driving sales for leading surgical robotics companies in his career. “We ar...

 PRESS RELEASE

Venus Concept Inc. Announces New Regulatory Clearances

Venus Concept Inc. Announces New Regulatory Clearances CE Mark Approval for Venus Bliss™️ for Non-Invasive Lipolysis of Abdomen & Flanks, Skin Tightening, Circumferential Reduction and Cellulite ReductionHealth Canada License to Market NeoGraft 2.0 for hair restoration TORONTO, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch